$2.2 billion for a Phase 1b asset. What is being bought is a target — CD122 — and the claim that it opens onto many diseases.
The worry was that fast weight loss costs bone. In 161 million records, semaglutide users broke fewer bones — which needs explaining, not just reporting.
Hunger and craving are different circuits. These drugs appear to act on both — in mice engineered with human receptors, which is the necessary caveat.
Decaf worked about as well as regular. That single detail rules out caffeine as the explanation and points somewhere else entirely.
A negative result with a practical consequence: if genes explained superagers, a blood test would identify them. It does not.
Two mechanisms in one tablet, beating either alone across eight studies — and doubling the ways to exceed a safe dose without noticing.
Vaccinate first and the antibody response is stronger early. Treat first and the arthritis improves sooner. By 12 weeks the antibody gap closes.
Gamma-delta T cells do not check MHC before killing. That single property is what makes an off-the-shelf cell therapy chemically possible.
Cost-effective per patient, unaffordable in aggregate. When 40% of adults qualify, those two things stop being contradictory.
An algorithm read 20,000 genes looking for hormones nobody had noticed. It found a 12-amino-acid peptide the human body already makes.
Everyone studies APOE4, the risk gene. Its protective counterpart may work by keeping neuronal DNA intact — a mechanism nobody was targeting.
The drug worked. Two patients developed a rare cancer, the same one that killed a competitor’s programme, and working was not enough.